Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA launches new priority review voucher program for select biopharmas
Clinical Data
Biotech
Immuneering sees 94% survival at 6 months in pancreatic cancer
The data emboldened the biotech to start planning a pivotal trial to support accelerated approval of its MEK inhibitor.
Nick Paul Taylor
Jun 17, 2025 10:55am
Lilly's amylin data impress with 11% weight loss, tolerability
Jun 16, 2025 4:55am
NewAmsterdam links lipid drug to drop in Alzheimer's biomarker
Jun 9, 2025 8:25am
Metsera posts amylin data, eyes monthly GLP-1 combo
Jun 9, 2025 7:00am
RegenXBio links DMD gene therapy to improved outcomes
Jun 5, 2025 8:52am
Vigil's rare brain disease drug flunks phase 2 study
Jun 4, 2025 9:45am